About Immuno-Biological Laboratories
Immuno-Biological Laboratories is a publicly listed company based in Fujioka (Japan) founded in 1982. Antibodies and diagnostic kits are developed and manufactured. The company has 58 employees. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Reagents and Kits and Proteomics.
Company details
Immuno-Biological Laboratories was established in 1982 in Fujioka, Japan, within the biotechnology sector. Amino-acid sequences are selected and developed for peptide immunogen synthesis. Polyclonal and monoclonal antibodies are produced based on these immunogens. ELISA assay kits, along with other in-vitro diagnostic products, are manufactured to support medical testing applications. Operations focus on research-driven production for global distribution.
- Headquarters Fujioka, Japan
- Employees 58
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Phone•••• ••••
- Website ibl-japan.co.jp
- Legal Name Immuno-Biological Laboratories Co., Ltd.
- Annual Revenue$6.27 M (USD)3.66as on Mar 31, 2026
- Net Profit$2.06 M (USD)32.11as on Mar 31, 2026
- EBITDA$1.88 M (USD)33.39as on Mar 31, 2026
- Latest Funding Round$11.85M (USD), Debt – Conventional
Dec 2016
- InvestorsTransgenic
& 1 more
- Employee Count58
Funding Insights of Immuno-Biological Laboratories
- Total Rounds 3
- Last Round Debt – Conventional — $11.85M
- First Round $1.78M
(Feb 2016)
- Investors Count 2
All 3 funding rounds of Immuno-Biological Laboratories with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2016 | $11.85M | Debt – Conventional | – | – | – |
| Apr 2016 | $2.75M | Debt – Conventional | – | – | |
| Feb 2016 | $1.78M | Post-IPO | – | – |
2 investors in total: 2 institutional.
Investors in Immuno-Biological Laboratories
Immuno-Biological Laboratories has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Transgenic and Towa Bank.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Commercial bank | 1917 | towabank.co.jp | Maebashi, Japan | |
Genomics, CRO, and pathological diagnosis services are provided by Transgenic. | 2000 | transgenic.co.jp | Kobe, Japan |
Investor details for Immuno-Biological Laboratories
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
IPO & Listings of Immuno-Biological Laboratories
Immuno-Biological Laboratories is a publicly listed company on the TSE with ticker symbol 4570 in Japan, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date16 Jul 2013
- Listed onTSE: 4570
- Listed entityImmuno-Biological Laboratories Co., Ltd.
- Exchange sectorHealth technology
- ISINJP3921300004
- Share price1,088.00 JPY (-1% on the day) · 2026-10-14
- Market capitalisation10,235,492,925.00 JPY
- Price to earnings27.5
- EPS (diluted, trailing year)39.55 JPY
- Dividend yield0.55%
- Volume (last session)44,500
Financials of Immuno-Biological Laboratories
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 1.00B JPY | 329.0M JPY | 299.8M JPY |
| 2024 | 969.5M JPY | 249.1M JPY | 224.8M JPY |
| 2023 | 816.7M JPY | 186.7M JPY | 113.3M JPY |
| 2022 | 794.6M JPY | -289.7M JPY | |
| 2021 | 647.6M JPY | -258.8M JPY |
Detailed financial statements for Immuno-Biological Laboratories
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Immuno-Biological Laboratories
4 dated milestones of Immuno-Biological Laboratories across 34 years, from founding to its latest funding, stage changes and deals.
- Founded Immuno-Biological Laboratories is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $1.8M.
- Funding Latest funding round, Debt – Conventional, of $11.8M.
Web traffic of Immuno-Biological Laboratories
The website of Immuno-Biological Laboratories (ibl-japan.co.jp) receives about 9.1K visits a month and ranks #1,016,643 among all websites worldwide, #1,243 in Biotechnology and Pharmaceuticals.
- Monthly visits9.1K
▼ 59.8% vs previous month
- Unique visitors12.6K
per month
- Global rank#1,016,643
among all websites
- Category rank#1,243
Health · Biotechnology and Pharmaceuticals
- Bounce rate43%
- Pages per visit3.1
- Average visit1 min 52 sec
- DevicesDesktop 65% · Mobile 35%
Websites whose visitors overlap most with Immuno-Biological Laboratories. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
namiki-s.co.jp | namiki-s.co.jp | 100% | #2,192,860 | – | |
| takara-bio.co.jp | 99% | 147K | #262,103 | View details | |
miltenyibiotec.co.jp | miltenyibiotec.co.jp | 98% | – | ||
n-genetics.com | n-genetics.com | 98% | #453,611 | – | |
falma.co.jp | falma.co.jp | 98% | #4,204,014 | – | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 16 similar websites and full traffic analytics for Immuno-Biological Laboratories
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 16 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Immuno-Biological Laboratories
Complete news archive for Immuno-Biological Laboratories
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Immuno-Biological Laboratories
Immuno-Biological Laboratories was founded in 1982 and raised its 1st funding round 34 years after it was founded.
Immuno-Biological Laboratories is headquartered in Fujioka, Japan. It is registered at Fujioka, Gunma, Japan.
Immuno-Biological Laboratories has 58 employees.
Annual revenue of Immuno-Biological Laboratories is $6.27M as on Mar 31, 2026.
Immuno-Biological Laboratories was established in 1982 in Fujioka, Japan, within the biotechnology sector. Amino-acid sequences are selected and developed for peptide immunogen synthesis. Polyclonal and monoclonal antibodies are produced based on these immunogens. ELISA assay kits, along with other in-vitro diagnostic products, are manufactured to support medical testing applications. Operations focus on research-driven production for global distribution.
Yes, Immuno-Biological Laboratories is publicly traded on TSE under the ticker symbol 4570.
Immuno-Biological Laboratories has 2 investors. Key investors include Transgenic, and Towa Bank.